InvestorsHub Logo
Followers 79
Posts 24490
Boards Moderated 1
Alias Born 09/08/2000

Re: None

Tuesday, 04/23/2024 8:26:48 AM

Tuesday, April 23, 2024 8:26:48 AM

Post# of 27395
IBRX - 5.89/5.91 Up from 4.94

Reported Earlier, ImmunityBio Has Received FDA Approval For ANKTIVA, A First-In-Class IL-15 Receptor Agonist, For BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.